Partial
Partially Aligned
Patient Risk:
Medium_to_high
Summary
Most dosing/mechanism/monitoring-related claims align with the label excerpts provided, but two safety-critical contraindication claims are contradicted by the label. Several other claims are unsupported/incorrectly characterized (e.g., missed-dose conditional timing, specific interaction effects, and adverse-effect frequency/category wording).
Category Scores
Accurate Statements
Ezetimibe works by inhibiting the absorption of cholesterol in the small intestine.
Supported by Mechanism of Action (12.1).
The recommended dose of ezetimibe is 10 mg orally once daily, administered with or without food.
Supported by Dosage and Administration (2).
If a dose is missed, it should be taken as soon as possible.
Supported by Dosage and Administration (2) and Patient Counseling (17).
Do not double the next dose to make up for a missed dose.
Supported by Dosage and Administration (2) and Patient Counseling (17).
Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ZETIA.
Supported by Dosage and Administration (2).
Ezetimibe may cause myopathy and rhabdomyolysis (muscle pain/tenderness/weakness with elevated CK; rhabdomyolysis).
Supported by Warnings and Precautions (5.3) and serious adverse reactions (6.1 referenced).
Consulting/providing interaction information and discussing all medication before taking with other medications is recommended.
Supported by Drug Interactions (7) and Patient Counseling (17).
Unsupported Statements
It is recommended to take ezetimibe at the same time every day to maintain a consistent level of the medication in the bloodstream.
Not supported by the provided label excerpts (2, 17) in the user material.
Ezetimibe should be taken at the same time each day.
Not supported by the provided label excerpts (2, 17).
If a missed dose is close to the time for the next dose, the missed dose should be skipped.
Not supported by the provided label excerpts; label only states not to double the next dose (2, 17).
It is not recommended to take ezetimibe more frequently than prescribed.
Not supported by the provided label excerpts.
Taking higher doses or taking ezetimibe more often than directed can increase the risk of side effects.
Not supported by the provided label excerpts.
Taking higher doses or taking ezetimibe more often than directed may not provide additional benefits.
Not supported by the provided label excerpts.
Ezetimibe may increase the risk of bleeding when taken with warfarin.
Not supported by the provided label excerpts (4, 5, 6, 7).
Ezetimibe may decrease the absorption of bile acid sequestrants.
The label excerpt describes decreased ezetimibe exposure with cholestyramine; it does not state that ezetimibe decreases absorption of bile acid sequestrants (7).
Decreased absorption of bile acid sequestrants may reduce their effectiveness.
Not supported by the provided label excerpt; the labeled interaction discusses potential reduction of ezetimibe efficacy with cholestyramine (7).
Your doctor may need to adjust your dosage of ezetimibe based on your response to treatment.
The label excerpt provided instructs to assess LDL-C as early as 4 weeks, but does not state dosage adjustment guidance based on response (2).
Regular monitoring of liver function tests may be necessary while taking ezetimibe.
Label excerpt supports performing liver enzyme testing as clinically indicated and considering withdrawal if ALT/AST persistently elevated; it does not explicitly support 'regular' broad liver function test monitoring (5.2).
Common side effects of ezetimibe include muscle pain.
Label excerpts discuss myopathy/rhabdomyolysis and muscle pain as part of myopathy, but do not support categorizing it as a 'common' side effect (5.3, 6).
Common side effects of ezetimibe include fatigue.
Fatigue is not supported in provided label excerpts (6).
Common side effects of ezetimibe include diarrhea.
Diarrhea is not supported in provided label excerpts (6).
Ezetimibe typically starts working within 2-4 weeks of treatment.
Label excerpt states maximal to near maximal response is generally achieved within 2 weeks; it does not support a 2–4 week typical window (14).
Contradictions
High
AI Statement
Ezetimibe is contraindicated in patients with active liver disease.
Label Reference
Contraindications (4); hepatic impairment guidance (8.7) states not recommended in moderate to severe hepatic impairment, but does not list active liver disease as a contraindication.
High
AI Statement
Ezetimibe is contraindicated in patients with a history of liver disease.
Label Reference
Contraindications (4); hepatic impairment guidance (8.7) does not list 'history of liver disease' as a contraindication.
Important Omissions
Missed-dose guidance is incomplete: the label excerpts provide 'take missed dose as soon as possible' and 'do not double the next dose' but do not support an additional conditional rule (skip missed dose if close to next dose).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium_to_high
Two contraindication statements are contradicted by the label excerpts provided (active liver disease; history of liver disease). This could lead to inappropriate exclusion criteria. Multiple other claims are unsupported or mischaracterize timing/frequency/side-effect categorization.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Contradicted contraindications (liver-related).
Suggested Improvement
Remove/replace the contradicted liver disease contraindications with the label-supported liver-related guidance (8.7: not recommended in moderate to severe hepatic impairment) and ensure all other claims (missed-dose conditional skipping, specific interaction directions, and adverse-effect frequency/category wording) are supported by the provided label excerpts.